- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ARRY 162 | ARRY-162 | ARRY-438162 | MEK-162 | MEK162 | Mektovi®
binimetinib is an approved drug (FDA and EMA (2018))
Compound class: Synthetic organic
Comment: Binimetinib is a potent non-ATP competitive inhibitor of MEK1/2 kinase activity  (link directly to abstract 794 online here).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Binimetinib received FDA approval as a treatment for advanced BRAF-mutant melanoma in June 2018. The approval is for a combination binimetinib plus the BRAF mutant kinase inhibitor, encorafenib. Results from Phase 3 clinical trial NCT01909453 which compared the combination of encorafenib plus binimetinib and encorafenib monotherapy to vemurafenib monotherapy in BRAF mutant melanoma were published in May 2018 . Phase 2 trial results for melanoma are available in .
Clinical studies in other solid tumour types and in hematological cancers are underway. Click here to link to ClinicalTrials.gov's full list of binimetinib (MEK162) trials.